International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis

Trial Profile

International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Eprodisate (Primary)
  • Indications Amyloid A amyloidosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Auven Therapeutics
  • Most Recent Events

    • 20 Jun 2016 According to a BELLUS Health media release, detailed results from the study will be presented July 6 at the XV International Symposium on Amyloidosis.
    • 20 Jun 2016 Primary endpoint has not been met. (Time from baseline to a persistent decrease in Creatinine clearance (CrCL) of 40% or more, a persistent increase in Serum Creatinine(SCr) of 80% or more, or progression to end-stage renal disease(ESRD)), as reported in a BELLUS Health media release.
    • 20 Jun 2016 Top-line results published in a BELLUS Health media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top